Cure
Overview
The latest women’s health venture capital news, updated monthly—tracking funding rounds of $3M or more across fertility & reproductive health, menopause & midlife, maternal health, oncology & diagnostics, endometriosis & hormonal conditions, and more.
For more, explore our Biotech Funding and Medtech Funding trackers, updated weekly.
October 2026
Pathos AI
Date: October 23, 2026 Series: Series E Amount: $237M Therapeutic area: Oncology & diagnostics Modality: AI drug development / small-molecule therapeutics Investors: Led by Bristol Myers Squibb; with participation from existing investors
Pathos AI closed a $237M Series E to scale its agentic AI drug development platform and advance its oncology pipeline, which includes AZD4241, an ERα-degrading PROTAC for ER-positive, HER2-negative breast cancer licensed from AstraZeneca.
Allswell
Date: October 14, 2026 Series: Seed Amount: $7M Therapeutic area: Other therapeutics Modality: Virtual behavioral health Investors: Led by Rethink Impact; Magnify Ventures, Ulu Ventures, and Hopelab Ventures, alongside existing investors Techstars and Amboy Street Ventures
Allswell raised a $7M seed round to expand its insurance-covered behavioral health platform for the LGBTQ+ community, which offers one-on-one virtual therapy and group programs covered by commercial insurance and Medicaid. The company will expand beyond Washington, D.C., Maryland, and Virginia, grow its therapist training program, and add psychiatric medication management in 2027.
Allara
Date: October 13, 2026 Series: Growth (not disclosed) Amount: $30M Therapeutic area: Endometriosis & hormonal conditions Modality: Virtual care Investors: Index Ventures and GV; with new investors Camino Partners, Foreground Capital, and Family Fund
Allara raised $30M, bringing total funding to $75M, to expand insurance-covered virtual care for hormonal, metabolic, and reproductive conditions. The company serves more than 120,000 women and plans to build AI tools that personalize care and support providers.
Collective X Health
Date: October 13, 2026 Series: Pre-seed Amount: $3.2M Therapeutic area: Other therapeutics Modality: Data platform / API Investors: Co-led by Council Capital and the Anthemis Female Innovators Lab Fund; with SoGal Ventures, Emerson Collective, and Muse Capital
Collective X Health came out of stealth with an oversubscribed $3.2M pre-seed round to license research-backed women’s health data to wearable makers, digital health platforms, and performance brands through an API.
KymaThera
Date: October 6, 2026 Series: Series B Amount: $80M Therapeutic area: Oncology & diagnostics Modality: Oral small-molecule therapeutic Investors: Led by Alta Partners; with existing investors Venrock and Foresite Capital and J. Wood Capital
KymaThera announced an $80M Series B to advance K-1728, an oral, pan-mutant selective PI3Kα inhibitor, into the clinic for HR-positive, HER2-negative breast cancer and PI3Kα-driven vascular malformations.
Biotia
Date: October 1, 2026 Series: Series A Amount: $9M Therapeutic area: Oncology & diagnostics Modality: Diagnostics / genetic sequencing Investors: DigitalDx Ventures, Convergent Ventures, Cloquet Capital Partners, Continuum Health Ventures, EGB Capital, and VillageMD co-founders Tim Barry and Dr. Clive Fields
Biotia raised an oversubscribed $9M to scale the BIOTIA-ID Urine Test, which uses genetic sequencing to identify the causes of recurrent and complicated UTIs. Funds will grow its New York City lab and develop additional women’s health diagnostics.
M&A and Partnerships
Ferring Pharmaceuticals acquires Gameto
Date: October 27, 2026 Deal type: Acquisition (merger agreement signed) Amount: Up to $1.38B, including milestones Therapeutic area: Fertility & reproductive health Modality: Cell therapy / IVF technology
Ferring signed an agreement to acquire Gameto for up to $1.38B, including development, regulatory, and commercial milestones. Gameto developed Fertilo, which uses stem cell–derived ovarian support cells to mature eggs in the lab and could cut IVF’s roughly two weeks of hormone injections to a few days. Fertilo is in a U.S. Phase 3 trial and is not FDA-approved.
Willow acquires Swehl and Momtech
Date: October 27, 2026 Deal type: Acquisitions Amount: Undisclosed Therapeutic area: Maternal health Modality: Consumer devices / digital education
Breast pump company Willow acquired Swehl, a breastfeeding education and community platform, and Momtech, maker of mōmi infant feeding technology. This deal follows Willow’s 2025 acquisition of Elvie.
Labcorp acquires Myriad Genetics’ prenatal testing business
Date: October 20, 2026 Deal type: Business acquisition Amount: $210M Therapeutic area: Maternal health Modality: Prenatal genetic testing
Labcorp agreed to acquire Myriad’s Prenatal Health business, including the Prequel, Foresight, SneakPeek, and FirstGene tests, which served more than 600,000 patients in the past year. Labcorp expects about $160M in first-year revenue. The deal is expected to close by early 2027.
Google Health and Flo Health
Date: October 12, 2026 Deal type: Strategic investment and multi-year partnership Amount: Undisclosed Therapeutic area: Endometriosis & hormonal conditions Modality: Digital health / wearables
Google Health made an investment in Flo Health as part of a multi-year partnership to combine Flo’s cycle data with wearable data. Starting in early 2027, Flo’s 80 million monthly users can opt in to sync with Google Health, which feeds their data to Google Health Coach.
September 2026
Tiny Health
Date: September 29, 2026 Series: Series B Amount: $33M Therapeutic area: Oncology & diagnostics Modality: Diagnostics / microbiome testing Investors: Led by B Capital; Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels, and Pari Passu Ventures
Tiny Health raised a $33M Series B to scale its microbiome intelligence platform, which sequences gut and vaginal microbiomes to generate personalized health insights. The company also launched a $5M Microbiome Research Program and serves nearly 200,000 patients and 6,000 providers.
Fate Therapeutics
Date: September 25, 2026 Series: Non-dilutive grant Amount: $15M Therapeutic area: Other therapeutics Modality: Cell therapy Investors: California Institute for Regenerative Medicine (CIRM)
Fate Therapeutics received a $15M CIRM CLIN2 grant to fund RECLAIM-LN, a potentially registrational Phase 2 trial of FT819, an off-the-shelf CAR T-cell therapy for lupus nephritis. Lupus overwhelmingly affects women.
Teal Health
Date: September 22, 2026 Series: Series A Amount: $22M Therapeutic area: Oncology & diagnostics Modality: Medical device / at-home screening Investors: Led by .406 Ventures; with Emerson Collective (managed by Yosemite), Forerunner, Serena Ventures, and new investor MPower Partners
San Francisco–based Teal Health raised $22M in Series A funding to expand access to the Teal Wand, the first FDA-authorized self-collection device for at-home HPV cervical cancer screening. The funding supports payer, health system, and employer partnerships ahead of broad insurance coverage beginning in January 2027.
Sling Therapeutics
Date: September 16, 2026 Series: Series C Amount: $123M Therapeutic area: Other therapeutics Modality: Oral small-molecule therapeutic Investors: Led by Forbion; with TPG Life Sciences Innovations and new investor Sectoral Asset Management
Sling Therapeutics closed a $123M Series C to advance linsitinib, an oral IGF-1R inhibitor for thyroid eye disease, through its global Phase 3 ORBIT trial. The FDA has granted linsitinib Fast Track designation. Thyroid eye disease is an autoimmune condition that occurs far more often in women.
Circle Pharma
Date: September 16, 2026 Series: Series E Amount: $92.5M Therapeutic area: Oncology & diagnostics Modality: Oral small-molecule therapeutic Investors: Led by The Column Group; with Nextech Invest, RA Capital Management, Euclidean Capital, and a strategic investment from Eli Lilly and Company
Circle Pharma announced an oversubscribed $92.5M Series E to advance CID-165, a first-in-class oral cyclin D1 inhibitor, into clinical development for ER-positive breast cancer. The company expects to enter the clinic in Q1 2027 and positions CID-165 as a potential new backbone therapy for the disease.
Evvy
Date: September 15, 2026 Series: Series B Amount: $40M Therapeutic area: Oncology & diagnostics Modality: Diagnostics / AI platform Investors: Led by Catalio Capital Management; with Rethink Impact, Muse Capital, and Alumni Ventures, alongside existing investors Labcorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures
Evvy raised an oversubscribed $40M Series B to validate a new generation of AI-driven diagnostics built on the largest proprietary clinical dataset on the vaginal microbiome. The company is expanding beyond vaginal health testing into fertility first, followed by infections, endometriosis, PCOS, perimenopause, and HPV progression.
M&A and Partnerships
EMD Serono acquires PostEra's fertility programs
Date: September 9, 2026 Deal type: Asset acquisition Amount: Undisclosed Therapeutic area: Fertility & reproductive health Modality: Oral small-molecule therapeutics (preclinical)
EMD Serono acquired PostEra's FSHR and LHCGR agonist programs, two preclinical oral alternatives to the injectable FSH and hCG drugs used in IVF. The programs could move IVF from daily injections to an all-oral regimen.
IVI RMA acquires Illume Fertility from The Fertility Partners
Date: September 4, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Fertility & reproductive health Modality: Fertility clinic network
The Fertility Partners completed the sale of Illume Fertility to IVI RMA North America, adding Illume's five locations across Connecticut and New York to IVI RMA's U.S. network.
August 2026
ProFound Therapeutics
Date: August 27, 2026 Series: Strategic investment Amount: Up to $35M ($20M initial, $15M milestone-based) Therapeutic area: Maternal health Modality: Drug discovery / protein therapeutics Investors: Gates Foundation
ProFound Therapeutics received an investment commitment of up to $35M from the Gates Foundation to discover biomarkers and first-in-class protein drugs for preeclampsia and eclampsia. The company will apply its ProFoundry platform and agentic AI tools to placental tissue and serum samples to identify previously undetected proteins.
Channel Medsystems
Date: August 20, 2026 Series: Series C (ongoing) Amount: $30M Therapeutic area: Endometriosis & hormonal conditions Modality: Medical device Investors: Led by InnovaHealth Partners
Channel Medsystems reached $30M in its ongoing Series C to accelerate commercial expansion of Cerene, a non-hormonal, incision-free endometrial cryotherapy treatment for heavy menstrual bleeding and dysmenorrhea. The 2.5-minute procedure is performed in an office or outpatient setting without general anesthesia.
M&A and Partnerships
Rael and TowerBrook Capital Partners
Date: August 24, 2026 Deal type: Strategic investment / partnership Amount: Undisclosed Therapeutic area: Other therapeutics Modality: Consumer health
Rael made a strategic partnership with TowerBrook Capital Partners to scale its holistic cycle care portfolio. Founded in Los Angeles in 2017 and led by CEO Yanghee Paik, Rael sells period care, skincare, and supplements built around the four phases of the menstrual cycle across more than 40,000 retail locations. The company had previously raised $59M over three rounds.
Essity acquires Kenvue’s Brazil feminine care portfolio
Date: August 20, 2026 Deal type: Acquisition Amount: $284M Therapeutic area: Other therapeutics Modality: Consumer health
Essity agreed to acquire Kenvue's feminine care business in Brazil for $284M, including the Carefree, Sempre Livre, and o.b. brands for sanitary pads, liners, and tampons, plus related manufacturing. Brazil is the world's fourth-largest feminine care market. Closing is expected in Q2 2027.
Ouma Health acquires a maternal-fetal medicine practice
Date: August 4, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Maternal health Modality: Telehealth / clinical practice
Ouma Health acquired a multisite maternal-fetal medicine practice led by Dr. Tamara Takoudes, adding clinical locations across Connecticut, Massachusetts, Maine, and New Hampshire. Ouma is the largest independent maternity telemedicine company founded and led by MFM physicians, and the deal pairs its national teleMFM network with in-person care as MFM workforce shortages limit access to high-risk pregnancy care.
July 2026
DITTO
Date: July 28, 2026 Series: Seed Amount: $6M (€5.2M) Therapeutic area: Endometriosis & hormonal conditions Modality: Consumer health / clinical research Investors: Led by FoodLabs; with Eka Ventures and angels
London-based DITTO raised $6M to scale its evidence-based menstrual health supplements and expand its clinical research program. Founded in 2024 by nutrition scientist Alice van der Schoot, the company's flagship Premenstrual Daily targets PMS and PMDD symptoms through a time-released beadlet system delivering ten clinical ingredients.
Yarrow Bioscience
Date: July 27, 2026 Series: Private placement, concurrent with merger Amount: ~$200M gross proceeds Therapeutic area: Other therapeutics Modality: Therapeutics (autoimmune thyroid disease) Investors: Led by RTW Investments; with OrbiMed, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners, and Perceptive Advisors
New Haven–based Yarrow Bioscience completed its merger with VYNE Therapeutics alongside roughly $200M in private placements and began dosing in a Phase 2a/2b trial of YB-101. The candidate targets Graves' disease and thyroid eye disease; Graves' affects women at roughly five to ten times the rate of men.
The American Baby Company
Date: July 23, 2026 Series: Seed Amount: $4M Therapeutic area: Fertility & reproductive health Modality: Care delivery / fertility clinic Investors: Wormhole Capital and Tower Research Ventures
The American Baby Company raised $4M to open its first clinic in West Palm Beach, Florida, this fall. Founded by Van Spina and reproductive endocrinologist Dr. Paul Magarelli, the company prices IVF at $8,995 and egg freezing at $4,995 with medications included, using stronger upfront diagnostics and protocol-driven care to cut costs.
Juno Bio
Date: July 16, 2026 Series: Seed Amount: $3.8M Therapeutic area: Endometriosis & hormonal conditions Modality: Diagnostics Investors: Led by Ada Ventures; with Artesian, Entrepreneur First, and Illumina Accelerator
Juno Bio raised $3.8M and opened the first CLIA-certified sequencing lab dedicated entirely to women's health, in Oakland, California. The platform scales precision vaginal microbiome testing and STI screening, giving clinicians actionable insight into infections, fertility, and menopausal health.
SONATA
Date: July 14, 2026 Series: Seed Amount: $7M Therapeutic area: Other therapeutics Modality: Preventive care membership / diagnostics Investors: Led by Lux Capital; with BoxGroup, Sunflower Capital, and angels including the founders of Ramp and Linear
SONATA launched a physician-led preventive health membership across New York, San Francisco, and Los Angeles with $7M in backing. The $2,500 annual membership combines whole-genome sequencing, more than 140 blood biomarkers, DNA methylation analysis, and wearable data with unlimited physician access and clinical AI built in-house.
Corner Health
Date: July 9, 2026 Series: Seed and Series A Amount: $32.5M Therapeutic area: Other therapeutics Modality: Care delivery / AI-enabled provider network Investors: Series A led by Oak HC/FT; with existing investors First Round Capital and Zigg Capital
Corner Health announced $32.5M in seed and Series A financing to help nurse practitioners start and scale their own primary care practices. The network spans more than 70 provider-owned practices across Arizona and Washington and enabled over 35,000 patient visits in the past year. The company positions the model as particularly relevant for women, who use healthcare services at higher rates than men.
Notable M&A and Partnerships DKSH acquires Meliane from Bayer
Date: July 27, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Fertility & reproductive health Modality: Pharmaceutical / contraception
DKSH signed an agreement to acquire rights to Meliane, a low-dose combined oral contraceptive, from Bayer across 30 markets in Europe, North Africa, Asia, and the Middle East. The 30-year-old brand generated approximately CHF 15M in net sales in 2025. Closing is expected in Q3 2026.
Wildflower Health acquires Every Mother
Date: July 21, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Maternal health Modality: Digital care platform
Wildflower Health acquired Every Mother, a digital pelvic floor and core rehabilitation platform, adding programs across pregnancy, postpartum recovery, surgical recovery, and perimenopause. The deal marks Wildflower's first move into direct-to-consumer care.
GoRocky acquires Kindred Health
Date: July 21, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Other therapeutics Modality: Telehealth / hybrid clinic
Philippines-based telehealth platform GoRocky acquired Kindred Health, a hybrid women's health provider offering consultations, diagnostics, ultrasounds, and care spanning infertility, menopause, and infectious disease through a virtual platform and a flagship clinic in Bonifacio Global City. More than 60% of GoRocky's weight management patients are women.
ONTO Health acquires LEVY Health
Date: July 7, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Fertility & reproductive health Modality: Clinical decision support software
ONTO Health acquired LEVY Health, a clinical decision support company providing precision diagnostics and patient intake for reproductive medicine. Funded by ONTO's recent Series A, the deal supports expansion across the U.S. and into the Gulf Cooperation Council region.
Genentech and Astex Pharmaceuticals
Date: July 6, 2026 Deal type: Research collaboration and license agreement Amount: Up to $490M ($25M upfront, plus milestones and royalties) Therapeutic area: Oncology & diagnostics Modality: Small-molecule therapeutics
Astex entered an exclusive worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to identify small-molecule candidates for breast cancer. Genentech takes sole responsibility for preclinical and clinical development and global commercialization. The program originated in Astex's alliance with Newcastle University and Cancer Research Horizons.
June 2026
Materna Medical
Date: June 30, 2026 Series: Series B3 Amount: $5M Therapeutic area: Maternal health Modality: Medical device Investors: InnovaHealth Partners, Wavemaker360 Health, and Band of Angels, with continued support from existing investors
Materna Medical closed a $5M B3 financing to advance its Ellora Obstetrical System, an investigational device designed to reduce pelvic floor muscle injury during vaginal delivery in first-time mothers. The funding supports the readout of its EASE pivotal trial, expanded channel access for Milli, its FDA-cleared vaginal dilator, and commercial manufacturing buildout. A first-in-class reimbursement code for the device is now active.
Clair Health
Date: June 17, 2026 Series: Seed Amount: $11.6M Therapeutic area: Hormonal conditions Modality: Wearable / continuous monitoring Investors: Led by Khosla Ventures; with a16z speedrun, Brydge Club, Treehub, Cartan Capital, Insiders VC, and Anne Wojcicki
Clair Health, founded by two recent Stanford grads, raised $11.6M to build the first noninvasive, continuous hormone monitor for women, tracking estrogen, progesterone, LH, and FSH without blood draws. A consumer launch is planned for late 2026.
Rejoni
Date: June 16, 2026 Series: Growth Amount: $25M Therapeutic area: Fertility & reproductive health Modality: Medical device Investors: ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital, and Sparta Group
Rejoni secured $25M in financing to accelerate its Juveena Hydrogel System toward FDA approval and commercial launch. The catheter-delivered device places a temporary hydrogel spacer in the uterine cavity to support endometrial healing and reduce intrauterine adhesions following intrauterine surgery.
Mammogen
Date: June 10, 2026 Series: Series A Amount: Up to $30M Therapeutic area: Oncology & diagnostics Modality: Blood test / diagnostic Investors: Led by a major U.S. public retirement system
Mammogen raised up to $30M to advance its RNA-powered blood test for earlier breast cancer detection and to reduce unnecessary biopsies.
Contraline
Date: June 2, 2026 Series: Series B Amount: $92.5M Therapeutic area: Fertility & reproductive health Modality: Hormonal drug (gel) Notable Investors: Co-led by BVF Partners and RA Capital Management; with GV, Lumira Ventures, and Invus
Charlottesville, Virginia–based Contraline raised $92.5M to advance NES/T, an investigational once-daily, reversible hormonal male contraceptive gel, into late-stage (Phase 3) development. The funds support its lead program and additional pipeline assets.
May 2026
Oli (Baymatob)
Date: May 26, 2026 Series: Series A3 Amount: $6.5M Therapeutic area: Maternal health Modality: Wearable device Investors: Scale Investors, Clare Ventures, and the University of Sydney
Australia-based Baymatob raised $6.5M to advance Oli, its wireless wearable for predictive maternal and fetal monitoring during labor, ahead of market entry. Oli has raised over $13M in private capital and over $9M in non-dilutive funding to date.
UroMems
Date: May 15, 2026 Series: Series D Amount: $60M Therapeutic area: Other therapeutics Modality: Implantable device Investors: Led by Ajax Health Fund I
French-American UroMems raised $60M, its largest round to date, to advance its smart, automated artificial urinary sphincter implant for stress urinary incontinence, a condition that disproportionately affects women.
April 2026
ScreenPoint Medical
Date: April 17, 2026 Series: Growth (existing investors) Amount: $16M ($14M equity + $2M non-dilutive grants) Therapeutic area: Oncology & diagnostics Modality: AI diagnostic software Investors: Insight Partners and Siemens Healthineers
Nijmegen, Netherlands–based ScreenPoint raised $16M to scale its Transpara breast-cancer detection AI, now deployed in 30+ countries with over 12 million mammograms processed.
Osteoboost Health
Date: April 15, 2026 Series: Seed Amount: $8M Therapeutic area: Menopause & midlife Modality: Wearable device Investors: Led by Ambit Health Ventures; with Emmeline Ventures, Disrupt Health Impact Fund, Esplanade Ventures, and Portfolia
Osteoboost Health raised $8M to scale its FDA-cleared wearable that treats low bone density in postmenopausal women with osteopenia through targeted vibration therapy.
ONTO Health
Date: April 15, 2026 Series: Series A Amount: $20M Therapeutic area: Fertility & reproductive health Modality: Digital health / AI care Investors: ARTIS and Humania
ONTO Health, led by reproductive endocrinologist Dr. Roohi Jeelani, raised $20M to expand its AI-enabled fertility and longevity care platform across the U.S. and into the Gulf Cooperation Council region. The platform combines evidence-based fertility care with AI diagnostics and clinical automation.
Wavelet Medical
Date: April 14, 2026 Series: Seed Amount: $7M Therapeutic area: Maternal health Modality: AI monitoring device Investors: Led by Aegis Ventures
Wavelet Medical raised $7M to bring the first non-invasive, AI-powered fetal brain (EEG) monitoring to labor and delivery, detecting fetal brain distress in real time.
Flora Fertility
Date: April 7, 2026 Series: Seed Amount: $5M Therapeutic area: Fertility & reproductive health Modality: Insurance / fintech Investors: Led by ManchesterStory; with Slauson & Co. and BDC
Flora Fertility raised $5M for individually owned fertility insurance that isn't tied to employment.
SimpliFed
Date: April 7, 2026 Series: Series A Amount: $10.8M Therapeutic area: Maternal health Modality: Digital health / virtual care Investors: Co-led by Morningside and Hesperia Capital; with Foreground Capital, AHA Social Impact Fund, and Elizabeth Street Ventures
SimpliFed, founded by Andrea Ippolito, raised $10.8M to expand from virtual lactation support into full virtual OB care, serving patients from pregnancy through postpartum in partnership with health systems and clinics.
March 2026
Nadia Care
Date: March 16, 2026 Series: Growth Amount: $12M Therapeutic area: Maternal health Modality: Care delivery / virtual + community Investors: Led by Valtruis and a national payer; with First Trust Capital Partners and RH Capital
Nadia Care (formerly Cayaba Care) raised $12M to expand its community-centered maternal care model across the U.S. Its model has produced a 60% reduction in NICU days and 38% lower preterm birth rates among members served through regional Medicaid plans.
May Health
Date: March 10, 2026 Series: Growth (existing + new investors) Amount: $11.7M Therapeutic area: Fertility & reproductive health Modality: Medical device Investors: Sofinnova Partners, Trill Impact, Bpifrance, and new investor Nexpring Health
May Health raised $11.7M to advance its Anavi System, a device for PCOS-related infertility, through its U.S. pivotal IDE trial (REBALANCE) and to support European launch planning.
February 2026
Sensei Biotherapeutics / Faeth Therapeutics
Date: February 18, 2026 Series: Acquisition + $200M private placement Amount: ~$200M Therapeutic area: Oncology & diagnostics Modality: Oral therapeutic (M&A) Investors: Private placement co-led by RA Capital Management, Vivo Capital, Cormorant Asset Management, and Fairmount
Sensei Biotherapeutics acquired Faeth Therapeutics alongside a $200M private placement, advancing Faeth's PIKTOR, an oral therapy targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancer.
Midi Health
Date: February 3, 2026 Series: Series D Amount: $100M (at $1B+ valuation) Therapeutic area: Menopause & midlife Modality: Digital health / virtual care Investors: Led by Goodwater Capital; with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens, and McKesson Ventures
Midi Health raised $100M, crossing a $1B valuation, to scale its virtual perimenopause and menopause platform across all 50 states, adding OB-GYN, cardiology, and dermatology services.
January 2026
Pee Safe
Date: January 2026 Series: Series C Amount: $32M Therapeutic area: Other therapeutics Modality: Consumer health Investors: Led by OrbiMed; with Alkemi Growth Capital
Pee Safe raised $32M to scale its period, feminine, and intimate-hygiene and personal-care business, expanding into 23 international markets.
Science&Humans
Date: January 2026 Series: Series A Amount: $7M Therapeutic area: Endometriosis & hormonal conditions Modality: Digital health / telehealth platform Investors: Led by Pender Ventures; with WELL Health Technologies, CIBC Innovation Banking, and Michele Romanow
Toronto-based Science&Humans raised $7M to scale its hormone-health platform across Canada, treating PCOS, PMS, PMDD, endometriosis, perimenopause, and menopause.
ShanX Medtech
Date: January 14, 2026 Series: Seed Amount: $28M Therapeutic area: Oncology & diagnostics Modality: Diagnostic device Investors: Borski Fund, NextGen Ventures, CbusineZ, BOM, and Invest-NL
Netherlands-based ShanX Medtech raised $28M for its ultra-rapid antimicrobial susceptibility testing platform, initially focused on UTIs, which disproportionately affect women.
Feminai
Date: January 12, 2026 Series: Seed Amount: $6M Therapeutic area: Oncology & diagnostics Modality: Wearable / AI Investors: Led by Vertex Ventures Israel; with ICI Fund, Fusion VC, Arben Ventures, and Cactus Capital
Israel-based Feminai raised $6M to develop its AI-powered wearable for at-home breast cancer screening.
BrightHeart
Date: January 8, 2026 Series: Series A Amount: $12.6M Therapeutic area: Maternal health (prenatal diagnostics) Modality: AI diagnostic software Investors: Co-led by Odyssée Venture and GO Capital; with Sofinnova Partners and the Mussallem CHD Alliance
BrightHeart (France/U.S.) raised over $12M to scale its FDA-cleared AI platform for prenatal ultrasound, which improves congenital heart defect detection to over 96%. Funds support U.S. commercialization and European expansion.
Pomelo Care
Date: January 8, 2026 Series: Series C Amount: $92M (at $1.7B valuation) Therapeutic area: Maternal health Modality: Digital health / virtual care Investors: Led by Stripes; with Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, and SV Angel
Pomelo Care raised $92M to grow its virtual maternity model into broader women's and children's health, including reproductive care, pediatrics, and menopause. The company now covers more than 25 million lives.







